vs
Side-by-side financial comparison of Clearfield, Inc. (CLFD) and Intellia Therapeutics, Inc. (NTLA). Click either name above to swap in a different company.
Clearfield, Inc. is the larger business by last-quarter revenue ($34.3M vs $23.0M, roughly 1.5× Intellia Therapeutics, Inc.). Clearfield, Inc. runs the higher net margin — -1.8% vs -416.2%, a 414.4% gap on every dollar of revenue. On growth, Intellia Therapeutics, Inc. posted the faster year-over-year revenue change (78.8% vs -3.2%). Clearfield, Inc. produced more free cash flow last quarter ($-2.4M vs $-69.4M). Over the past eight quarters, Clearfield, Inc.'s revenue compounded faster (-3.5% CAGR vs -10.8%).
Clearfield, Inc. is a company headquartered in Minneapolis, Minnesota. The company produces fiber optic products.
Intellia Therapeutics, Inc. is an American clinical-stage biotechnology company focused on developing novel, potentially curative therapeutics leveraging CRISPR-based technologies. The company's in vivo programs use intravenously administered CRISPR as the therapy, in which the company's proprietary delivery technology enables highly precise editing of disease-causing genes directly within specific target tissues. Intellia's ex vivo programs use CRISPR to create the therapy by using engineere...
CLFD vs NTLA — Head-to-Head
Income Statement — Q1 FY2026 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $34.3M | $23.0M |
| Net Profit | $-614.0K | $-95.8M |
| Gross Margin | 33.2% | — |
| Operating Margin | -5.3% | -428.9% |
| Net Margin | -1.8% | -416.2% |
| Revenue YoY | -3.2% | 78.8% |
| Net Profit YoY | 67.8% | 25.7% |
| EPS (diluted) | $-0.04 | $-0.81 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $34.3M | $23.0M | ||
| Q3 25 | $23.4M | $13.8M | ||
| Q2 25 | $49.9M | $14.2M | ||
| Q1 25 | $47.2M | $16.6M | ||
| Q4 24 | $29.7M | $12.9M | ||
| Q3 24 | $5.6M | $9.1M | ||
| Q2 24 | $48.8M | $7.0M | ||
| Q1 24 | $36.9M | $28.9M |
| Q4 25 | $-614.0K | $-95.8M | ||
| Q3 25 | $-9.1M | $-101.3M | ||
| Q2 25 | $1.6M | $-101.3M | ||
| Q1 25 | $1.3M | $-114.3M | ||
| Q4 24 | $-1.9M | $-128.9M | ||
| Q3 24 | — | $-135.7M | ||
| Q2 24 | $-447.0K | $-147.0M | ||
| Q1 24 | $-5.9M | $-107.4M |
| Q4 25 | 33.2% | — | ||
| Q3 25 | 53.2% | — | ||
| Q2 25 | 30.5% | — | ||
| Q1 25 | 30.1% | — | ||
| Q4 24 | 29.2% | — | ||
| Q3 24 | — | — | ||
| Q2 24 | 21.9% | — | ||
| Q1 24 | 7.7% | — |
| Q4 25 | -5.3% | -428.9% | ||
| Q3 25 | 10.3% | -808.9% | ||
| Q2 25 | 3.0% | -772.2% | ||
| Q1 25 | 0.6% | -726.6% | ||
| Q4 24 | -6.9% | -1059.9% | ||
| Q3 24 | — | -1589.0% | ||
| Q2 24 | -4.7% | -1998.6% | ||
| Q1 24 | -26.4% | -394.0% |
| Q4 25 | -1.8% | -416.2% | ||
| Q3 25 | -38.8% | -735.2% | ||
| Q2 25 | 3.2% | -710.8% | ||
| Q1 25 | 2.8% | -687.6% | ||
| Q4 24 | -6.4% | -1001.2% | ||
| Q3 24 | — | -1489.5% | ||
| Q2 24 | -0.9% | -2112.6% | ||
| Q1 24 | -16.0% | -371.3% |
| Q4 25 | $-0.04 | $-0.81 | ||
| Q3 25 | $-0.65 | $-0.92 | ||
| Q2 25 | $0.11 | $-0.98 | ||
| Q1 25 | $0.09 | $-1.10 | ||
| Q4 24 | $-0.13 | $-1.27 | ||
| Q3 24 | — | $-1.34 | ||
| Q2 24 | $-0.04 | $-1.52 | ||
| Q1 24 | $-0.40 | $-1.12 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $96.4M | $449.9M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $249.7M | $671.4M |
| Total Assets | $268.1M | $842.1M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $96.4M | $449.9M | ||
| Q3 25 | $106.0M | $511.0M | ||
| Q2 25 | $117.2M | $459.7M | ||
| Q1 25 | $112.0M | $503.7M | ||
| Q4 24 | $113.0M | $601.5M | ||
| Q3 24 | $129.0M | $658.1M | ||
| Q2 24 | $123.8M | $691.1M | ||
| Q1 24 | $142.9M | $791.3M |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | $2.2M | — | ||
| Q2 24 | $2.1M | — | ||
| Q1 24 | — | — |
| Q4 25 | $249.7M | $671.4M | ||
| Q3 25 | $256.2M | $748.4M | ||
| Q2 25 | $264.5M | $715.3M | ||
| Q1 25 | $265.9M | $779.9M | ||
| Q4 24 | $267.4M | $872.0M | ||
| Q3 24 | $275.8M | $962.6M | ||
| Q2 24 | $274.6M | $971.1M | ||
| Q1 24 | $279.2M | $1.0B |
| Q4 25 | $268.1M | $842.1M | ||
| Q3 25 | $306.2M | $925.3M | ||
| Q2 25 | $314.7M | $898.9M | ||
| Q1 25 | $310.9M | $986.2M | ||
| Q4 24 | $303.2M | $1.2B | ||
| Q3 24 | $315.3M | $1.2B | ||
| Q2 24 | $318.1M | $1.2B | ||
| Q1 24 | $315.4M | $1.3B |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | 0.01× | — | ||
| Q2 24 | 0.01× | — | ||
| Q1 24 | — | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-1.4M | $-69.3M |
| Free Cash FlowOCF − Capex | $-2.4M | $-69.4M |
| FCF MarginFCF / Revenue | -7.1% | -301.6% |
| Capex IntensityCapex / Revenue | 2.9% | 0.5% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | — | $-395.9M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $-1.4M | $-69.3M | ||
| Q3 25 | — | $-76.9M | ||
| Q2 25 | $7.9M | $-99.6M | ||
| Q1 25 | $3.0M | $-148.9M | ||
| Q4 24 | $7.2M | $-85.2M | ||
| Q3 24 | $22.2M | $-84.8M | ||
| Q2 24 | $4.0M | $-58.2M | ||
| Q1 24 | $-5.7M | $-120.7M |
| Q4 25 | $-2.4M | $-69.4M | ||
| Q3 25 | — | $-76.9M | ||
| Q2 25 | $7.5M | $-99.9M | ||
| Q1 25 | $654.0K | $-149.7M | ||
| Q4 24 | $5.1M | $-86.2M | ||
| Q3 24 | $18.2M | $-86.1M | ||
| Q2 24 | $2.8M | $-59.2M | ||
| Q1 24 | $-7.7M | $-123.2M |
| Q4 25 | -7.1% | -301.6% | ||
| Q3 25 | — | -558.2% | ||
| Q2 25 | 15.1% | -701.0% | ||
| Q1 25 | 1.4% | -900.1% | ||
| Q4 24 | 17.1% | -669.4% | ||
| Q3 24 | 323.0% | -945.2% | ||
| Q2 24 | 5.8% | -850.9% | ||
| Q1 24 | -20.8% | -425.7% |
| Q4 25 | 2.9% | 0.5% | ||
| Q3 25 | 2.0% | 0.2% | ||
| Q2 25 | 0.8% | 1.7% | ||
| Q1 25 | 5.1% | 4.4% | ||
| Q4 24 | 7.0% | 7.6% | ||
| Q3 24 | 71.4% | 14.0% | ||
| Q2 24 | 2.5% | 14.5% | ||
| Q1 24 | 5.3% | 8.7% |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | 4.93× | — | ||
| Q1 25 | 2.30× | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
CLFD
Segment breakdown not available.
NTLA
| Avencell Therapeutics Inc | $21.0M | 91% |
| Other | $1.0M | 4% |
| Avencell | $1.0M | 4% |
